Google
Trusted Resources: News & Events
Latest announcements and gatherings
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell Disease
The California Institute for Regenerative Medicine (CIRM) and the National Heart, Lung and Blood Institute (NHLBI) have entered into a “landmark” collaboration to co-fund and help speed the development of cell and gene therapies to cure sickle cell disease (SCD), according to a press release.
The agreement was created under the National Institutes of Health’s “Cure Sickle Cell” initiative, led by NHLBI, the goal of which is to take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based therapies into clinical trials within five to 10 years.
This new collaboration will take advantage of CIRM’s vast resources and expertise, which have already resulted in more than 50 clinical trials in stem cell and regenerative medicine, and will provide lines of co-funding to CIRM-sponsored research.
“There is a real need for a new approach to treating SCD and making life easier for people with SCD and their families,” said Adrienne Shapiro, mother of a child with the disease and co-founder of Axis Advocacy.
+myBinderRelated Content
-
Novel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
-
Shared Decision Making for Hydroxyurea Treatment Initiation in Children With Sickle Cell AnemiaClinical trials have demonstrated hydrox...
-
L-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
Women with Sickle Cell Disease and Postpartum Care: What to Know After Delivering Your BabyPostpartum care is health care you get a...
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients Wi...Sancilio Pharmaceuticals Company, Inc. (...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.